Stockreport

JPM26: Sanofi's COAST 1 clinical trials exhibit positive results, with researchers optimistic for COAST 2 results for amlitelimab [Yahoo! Finance]

Sanofi - American Depositary Shares  (SNY) 
US:NYSE Investor Relations: sanofi.com/en/investors
PDF Among these, one that will be keenly watched is Phase III COAST-2 (NCT06181435) data readout for amlitelimab for atopic dermatitis (AD), which, if positive, will pave t [Read more]